<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02678117</url>
  </required_header>
  <id_info>
    <org_study_id>NCI,IRB 2010014053.3</org_study_id>
    <nct_id>NCT02678117</nct_id>
  </id_info>
  <brief_title>Analgesic Potentials of Preoperative Pregabalin,Magnesium Sulphate and Their Combination in Acute Post-thoracotomy Pain</brief_title>
  <official_title>Analgesic Potentials of Preoperative Oral Pregabalin,Intravenous Magnesium Sulphate and Their Combination in Acute Post-thoracotomy Pain.(Randomized,Double-Blind Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Egypt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of giving preoperative adjuvant drug as pregabalin or
      magnesium sulphate or a combination of both drugs to decrease postoperative morphine
      consumption and pain intensity in the first 24 hours in postoperative period . quarter of
      patients receive single dose oral pregabalin 300mg 1 hour preoperatively ,other quarter
      receive single intravenous Magnesium sulphate 50mg per Kg over 200ml saline over 20 minutes
      preoperatively , other quarter receive combination of both drugs , the last quarter receive
      placebo drugs . All patients receive 0.1mg per Kg intravenous morphine sulphate
      intraoperatively
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Magnesium (Mg) acts on N-methyl-D-aspartate (NMDA) receptor as a non-competitive antagonist
      with antinociceptive effects.

      Gabapentin is an alkylated analogue of gammaaminobutyric acid (GABA) developed primarily as
      an anticonvulsant drug. It was described as an analgesic drug for the treatment of
      neuropathic pain in the 1990s. Although it is named Gabapentin,it does not bind at the GABA A
      or GABA B receptor. It binds with high affinity for the α2δ subunit of the presynaptic
      voltage-gated calcium channels, which reduce calcium-dependent release of pro-nociceptive
      neurotransmitters in the pain pathways. Pregabalin is a structural analogue of GABA was
      introduced after Gabapentin. If we used these drugs in combination to opioids preoperatively
      as preventive analgesia may decrease postoperative opioid consumption and pain intensity.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total morphine consumption</measure>
    <time_frame>First 24 hours in postoperative period</time_frame>
    <description>patients are given regular intravenous morphine through patient controlled analgesia (PCA) and morphine consumption calculated from the PCA device</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain intensity using Visual Analogue Scale</measure>
    <time_frame>First 24 hours in postoperative period</time_frame>
    <description>Assessment of pain intensity every 4 hours in the first 24 hours in postoperative period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery Time</measure>
    <time_frame>Immediately after ending the surgery</time_frame>
    <description>Time taken for recovery of the patient to be fully awake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>First 24 hours in postoperative period</time_frame>
    <description>Assessment of Heart Rate every 4 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>First 24 hours in postoperative period</time_frame>
    <description>Assessment of Blood Pressure every 4 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen saturation</measure>
    <time_frame>First 24 hours in postoperative period</time_frame>
    <description>Assessment of Oxygen saturation every 4 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Rate</measure>
    <time_frame>First 24 hours in postoperative period</time_frame>
    <description>Assessment of Respiratory Rate every 4 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative nausea and vomiting</measure>
    <time_frame>First 24 hours in postoperative period</time_frame>
    <description>Postoperative nausea and vomiting scale (none 0, mild 1, moderate 2 , sever 3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects from the used drugs</measure>
    <time_frame>First 24 hours in postoperative period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation score</measure>
    <time_frame>First 24 hours in postoperative period</time_frame>
    <description>Using Ramsay Sedation score</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Pregabalin &amp; placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>: will receive single dose oral Pregabalin 300 mg one hour preoperative and 200 ml of normal saline over 20 min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Magnesium sulphate &amp; Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>will receive preoperative single dose IV Magnesium Sulphate 50mg /kg infused over 20 minutes diluted in 200 ml normal saline and a placebo capsule similar to pregabalin 300 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregabalin &amp; Magnesium sulphate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>: will receive single dose oral pregabalin 300mg one hour preoperative and single dose IV Magnesium Sulphate 50mg /kg infused over 20 minutes diluted in 200 ml normal saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>will receive placebo medications at the same time and route of administration of other groups.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin &amp; Placebo</intervention_name>
    <arm_group_label>Pregabalin &amp; placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium sulphate &amp; Placebo</intervention_name>
    <arm_group_label>Magnesium sulphate &amp; Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin &amp; Magnesium sulphate</intervention_name>
    <arm_group_label>Pregabalin &amp; Magnesium sulphate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ASA status of1 or 2

          2. Patients undergoing thoracotomy

          3. Body mass index (BMI): Less than forty and more than twenty.

        Exclusion Criteria:

        - 1. Known sensitivity or contraindication to drugs used in the study. 2. History of
        psychological disorders and/or chronic pain. 3. Patients receiving medical therapies that
        are considered to result in tolerance to opioids.

        4. Significant liver or kidney diseases that will affects the pharmacokinetics of study
        drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naglaa A Ahmed, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed S Ahmed</last_name>
    <phone>+20 01098426689</phone>
    <email>Dr_mido12@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ashraf M Heikal, MD</last_name>
    <phone>+2001226564878</phone>
    <email>ashrafyheikal@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Cairo</city>
        <zip>11796</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed S Ahmed</last_name>
      <phone>+20 01098426689</phone>
      <email>Dr_mido12@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Sagit M, Yalcin S, Polat H, Korkmaz F, Cetinkaya S, Somdas MA. Efficacy of a single preoperative dose of pregabalin for postoperative pain after septoplasty. J Craniofac Surg. 2013 Mar;24(2):373-5. doi: 10.1097/SCS.0b013e31827fece5.</citation>
    <PMID>23524696</PMID>
  </reference>
  <reference>
    <citation>Kiran S, Gupta R, Verma D. Evaluation of a single-dose of intravenous magnesium sulphate for prevention of postoperative pain after inguinal surgery. Indian J Anaesth. 2011 Jan;55(1):31-5. doi: 10.4103/0019-5049.76605.</citation>
    <PMID>21431050</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2016</study_first_submitted>
  <study_first_submitted_qc>February 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2016</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Institute, Egypt</investigator_affiliation>
    <investigator_full_name>Ahmed Salah Ahmed Abd Elgalil</investigator_full_name>
    <investigator_title>Demonstrator in anaesthesia department, National Cancer Institute, Egypt</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Pregabalin</mesh_term>
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data for all primary and secondary outcome measures will be available within 6 months of study completion</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

